A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure

Antonis, A.F.G.; Bruschke, Christianne; Rueda, Paloma; Maranga, Luís; Casal, J. Ignacio; Vela, Carmen; Hilgers, Luuk A.Th.; Belt, Peter B. G. M.; Weerdmeester, K.; Carrondo, Manuel J.T.; Langeveld, J.P.M.

doi:10.1016/j.vaccine.2006.03.089

Cited by 78 publications

(58 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Expression of the HIV or simian immunodeficiency virus (SIV) Gag and Env proteins results in the self-assembly of a core structure which is released by budding at the cell surface to produce particles containing Env that are similar in size to viruses but lack viral genetic materials. VLP-based vaccines are currently under investigation for several families of human viruses, including hepatitis viruses, papillomavirus, rotavirus, parvovirus, and influenza virus (3,8,17,21,39). Several studies have demonstrated the induction of neutralizing antibodies by HIV VLP immunization using murine models (9,13,52) or primates (33).…”

mentioning

confidence: 99%

Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- MacrophageColony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles

Skountzou

Quan

Gangadhara

et al. 2007

J Virol

View full text Add to dashboard Cite

The rapid worldwide spread of human immunodeficiency virus (HIV) mandates the development of successful vaccination strategies. Since live attenuated HIV is not accepted as a vaccine due to safety concerns, virus-like particles (VLPs) offer an attractive safe alternative because they lack the viral genome yet they are perceived by the immune system as a virus particle. We hypothesized that adding immunostimulatory signals to VLPs would enhance their efficacy. To accomplish this we generated chimeric simian immunodeficiency virus (SIV) VLPs containing either glycosylphosphatidylinositol (GPI)-anchored granulocyte-macrophage colonystimulating factor (GM-CSF) or CD40 ligand (CD40L) and investigated their biological activity and ability to enhance immune responses in vivo. Immunization of mice with chimeric SIV VLPs containing GM-CSF induced SIV Env-specific antibodies as well as neutralizing activity at significantly higher levels than those induced by standard SIV VLPs, SIV VLPs containing CD40L, or standard VLPs mixed with soluble GM-CSF. In addition, mice immunized with chimeric SIV VLPs containing either GM-CSF or CD40L showed significantly increased CD4 ؉ -and CD8 ؉ -T-cell responses to SIV Env, compared to standard SIV VLPs. Taken together, these results demonstrate that the incorporation of immunostimulatory molecules enhances humoral and cellular immune responses. We propose that anchoring immunostimulatory molecules into SIV VLPs can be a promising approach to augmenting the efficacy of VLP antigens.

show abstract

mentioning

confidence: 99%

Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- MacrophageColony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles

Skountzou

Quan

Gangadhara

et al. 2007

J Virol

View full text Add to dashboard Cite

show abstract

“…De esta forma, en cada VLP hay varias copias del epítopo, generándose una respuesta inmune frente a la cápsida y frente al epítopo. Existen numerosos trabajos que describen su capacidad protectora (Antonis et al, 2006;Rueda et al, 1999).…”

Section: Las Vacunas En Veterinariaunclassified

La biotecnología en sanidad animal

García

Casares

Moran

et al. 2014

Arbor

View full text Add to dashboard Cite

RESUMEN: El crecimiento de la población mundial en los próxi-mos años, provocará un incremento en la demanda de alimentos. Como consecuencia, el número de animales de producción sufrirá un aumento importante y la Sanidad Animal constituirá un elemento crítico a la hora de tratar y prevenir las enfermedades, garantizando el abastecimiento y la seguridad. La biotecnología contribuye de múltiples formas al desarrollo de la Sanidad Animal. Fundamentalmente, aporta herramientas que ayudan al control y erradicación de las enfermedades. El desarrollo de la ingeniería genética en las últimas décadas ha favorecido el avance de la industria biotecnológica aplicada a la sanidad humana y animal. Existen un gran número de ensayos de diagnóstico basados en desarrollos biotecnológicos, así mismo, cada vez hay más vacunas recombinantes contra enfermedades animales. La prevención y control eficientes de las enfermedades dependerán de mecanismos de detección temprana, que faciliten la toma de decisiones y una respuesta rápida. PALABRAS CLAVE:Vacunación; VLPs; diagnóstico; inmunoensayos; DIVA; ensayos múltiples; ensayos de campo; PCR.ABSTRACT: The growth of the world population in forthcoming years will cause an increase in the demand of food. As a result, the number of working animals is set to rise significantly and Animal Health will become a vital issue when it comes to treating and preventing diseases, and guaranteeing and uninterrupted and safe food supply. Biotechnology contributes to the development of Animal Health in many ways. First and foremost, it provides tools that help control and eradicate diseases. The progress of genetic engineering in recent decades has underpinned the development of the biotechnology industry applied to human and animal health. There are a large number of diagnostic tests based on biotechnological developments, and there is also an increase in the use of recombinant vaccines against animal diseases. An effective prevention and control of diseases will depend on early detection mechanisms that facilitate decisionmaking and enable a rapid response. KEYWORDS:Vaccination; VLPs; diagnostic; immunoassays; DIVA; multiplex assays; field tests; PCR.

show abstract

“…21,22 Vaccination trials of CPV VLPs in dogs and PPV VLPS in pigs were highly encouraging. 21,23 In one efficacy assay dogs that received as little as or 10 µg or 25 µg of CPV VLP were completely protected from virus infection when challenged with virulent virus. Furthermore a single subcutaneous dose of 3 µg same CPV VLP with 50 µg ISCOM adjuvant was able to protect mink against challenge with the antigenically similar virus, Virus-like particles as a vaccine delivery system mink enteritis virus (MEV).…”

Section: Vlps Produced For Structurally Simple Non-enveloped Virusesmentioning

confidence: 99%

“…21 Similarly it has been reported recently that a single immunization with 0.7 µg of PPV (porcine starin) VLPs yielded complete protection in targeted animals against infectious PPV strains. 23 Indeed microgram doses of VLPs in gilts were not only highly immunogenic, but were also very efficient in preventing trans-plancental virus transmission and significantly reduced the number of reproductive failures. In addition, the feasibility of safe large-scale production of the porcine parvovirus VLP vaccine has been established complying with the European Pharmacopoeia requirements.…”

Section: Vlps Produced For Structurally Simple Non-enveloped Virusesmentioning

confidence: 99%

Virus‑like particles as a vaccine delivery system: Myths and facts

Roy¹,

Noad²

2008

Human Vaccines

150

View full text Add to dashboard Cite

Vaccines against viral disease have traditionally relied on attenuated virus strains or inactivation of infectious virus. Subunit vaccines based on viral proteins expressed in heterologous systems have been effective for some pathogens, but have often suffered from poor immunogenicity due to incorrect protein folding or modification. In this review we focus on a specific class of viral subunit vaccine that mimics the overall structure of virus particles and thus preserves the native antigenic conformation of the immunogenic proteins. These virus-like particles (VLPs) have been produced for a wide range of taxonomically and structurally distinct viruses, and have unique advantages in terms of safety and immunogenicity over previous approaches. With new VLP vaccines for papillomavirus beginning to reach the marketplace we argue that this technology has now 'come-of-age' and must be considered a viable vaccine strategy.

show abstract

A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure

Cited by 78 publications

References 36 publications

Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- MacrophageColony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles

Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- MacrophageColony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles

La biotecnología en sanidad animal

Virus‑like particles as a vaccine delivery system: Myths and facts

Contact Info

Product

Resources

About